Clinical Decision Systems Support the U-PGx Project
By George P. Patrinos  |  Apr 13, 2022
Clinical Decision Systems Support the U-PGx Project
Image courtesy of and under license from
The Ubiquitous Pharmacogenomics (U-PGx) consortium has launched the U-PGx project in an effort to overcome existing barriers and deficiencies in healthcare systems and health infrastructure so as to establish a clinical decision support framework to deliver care that is more personalized and cost-effective, adaptable and able to be implemented in many countries, regardless of language, infrastructure, and healthcare system characteristics.

PATRAS, GREECE - Clinical pharmacogenomics (PGx) is the low-hanging fruit on the way to realizing personalized medicine in routine clinical care, given the availability of guidelines that provide evidence-based therapeutic recommendations for more than 200 gene-drug pairs. On this basis, clinical decision support (CDS) systems are indispensable components of PGx implementation, as they document the vast amounts of information contained within a patient’s PGx results and turn these into clinically actionable, concise therapeutic recommendations.

While the implementation of PGx-guided therapy has gained momentum in certain specialized early adopter sites, particularly in the United States, the pace of adoption in other regions such as Europe, the Middle East and Asia has been catching up in recent years. Some of the main challenges still hindering the implementation of PGx in clinical practice are the limitations and fragmentation in the current European healthcare landscape in the availability, capability, and interconnectedness of Electronic Health Record Systems (EHRs), which form the prerequisite for the most efficient delivery of PGx CDS, i.e., through the display of automatic alerts during the prescribing process. 

In order to alleviate and overcome these and other obstacles, the Ubiquitous Pharmacogenomics (U-PGx) consortium ( was set up in 2016 with three primary aims: (a) to address current barriers to PGx implementation, including the provision of enabling tools; (b) to yield scientific evidence for the improvement of patient outcomes through pre-emptive PGx testing - where an individual is tested for a panel of multiple genes at once instead of having multiple single gene tests conducted over time, which facilitates PGx-guided treatment for a number of gene-drug combinations throughout an individual’s life - by means of a prospective, randomized clinical study in more than 20

The content herein is subject to copyright by The Yuan. All rights reserved. The content of the services is owned or licensed to The Yuan. Such content from The Yuan may be shared and reprinted but must clearly identify The Yuan as its original source. Content from a third-party copyright holder identified in the copyright notice contained in such third party’s content appearing in The Yuan must likewise be clearly labeled as such.
Continue reading
Buy this article for only US$1.99
- or -
Continue with Linkedin Continue with Google
Share your thoughts.
The Yuan wants to hear your voice. We welcome your on-topic commentary, critique, and expertise. All comments are moderated for civility.